Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 4 | 5 |
| 1.1 List of Tables | 6 | 1 |
| 1.2 List of Figures | 6 | 3 |
| 2 Introduction | 9 | 23 |
| 2.1 Therapy Area Introduction | 9 | 1 |
| 2.2 Symptoms | 10 | 1 |
| 2.3 Etiology and Pathophysiology | 11 | 1 |
| 2.3.1 Etiology | 11 | 1 |
| 2.3.2 Pathophysiology | 12 | 1 |
| 2.3.3 Tumor Initiation | 13 | 1 |
| 2.3.4 Enhanced Growth, Evasion of Apoptosis and Replicative Immortality | 14 | 3 |
| 2.3.5 Tumor Metabolic Shift | 17 | 1 |
| 2.3.6 Tumor Progression, Invasion and Metastasis | 17 | 2 |
| 2.3.7 Evasion of the Immune Response | 19 | 1 |
| 2.3.8 Cancer Stem Cells | 20 | 1 |
| 2.4 Co-morbidities and Complications | 20 | 1 |
| 2.5 Epidemiology Patterns Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates | 21 | 1 |
| 2.5.1 Breast Cancer | 22 | 1 |
| 2.5.2 Colorectal Cancer | 22 | 1 |
| 2.5.3 Lung Cancer | 23 | 1 |
| 2.5.4 Prostate Cancer | 24 | 1 |
| 2.6 Treatment | 25 | 1 |
| 2.6.1 Surgery and Radiation Therapy | 26 | 1 |
| 2.6.2 Chemotherapy | 27 | 2 |
| 2.6.3 Hormonal Therapies | 29 | 1 |
| 2.6.4 Targeted Therapies | 30 | 2 |
| 3 Key Marketed Products | 32 | 13 |
| 3.1 Overview | 32 | 1 |
| 3.2 Avastin (bevacizumab) | 33 | 2 |
| 3.3 Herceptin (trastuzumab) | 35 | 2 |
| 3.4 Alimta (pemetrexed) | 37 | 1 |
| 3.5 Zytiga (abiraterone acetate) | 38 | 1 |
| 3.6 Xtandi (enzalutamide) | 39 | 1 |
| 3.7 Perjeta (pertuzumab) | 40 | 1 |
| 3.8 Tarceva (erlotinib hydrochloride) | 41 | 2 |
| 3.9 Yervoy (ipilimumab) | 43 | 1 |
| 3.10 Conclusion | 44 | 1 |
| 4 Pipeline Landscape Assessment | 45 | 32 |
| 4.1 Overview | 45 | 1 |
| 4.2 Pipeline Development Landscape | 45 | 4 |
| 4.3 Molecular Targets in the Pipeline | 49 | 3 |
| 4.4 Clinical Trials | 52 | 1 |
| 4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target | 53 | 1 |
| 4.4.1.1 Indication | 53 | 1 |
| 4.4.1.2 Molecule Type | 54 | 1 |
| 4.4.1.3 Molecular Target | 55 | 1 |
| 4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target | 56 | 1 |
| 4.4.2.1 Indication | 57 | 1 |
| 4.4.2.2 Molecule Type | 58 | 1 |
| 4.4.2.3 Molecular Target | 59 | 1 |
| 4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target | 60 | 1 |
| 4.4.3.1 Indication | 61 | 1 |
| 4.4.3.2 Molecule Type | 62 | 1 |
| 4.4.3.3 Molecular Target | 63 | 1 |
| 4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target | 64 | 1 |
| 4.4.4.1 Indication | 65 | 1 |
| 4.4.4.2 Molecule Type | 66 | 1 |
| 4.4.4.3 Molecular Target | 67 | 1 |
| 4.4.5 Conclusion | 68 | 1 |
| 4.5 Assessment of Key Pipeline Products | 69 | 1 |
| 4.5.1 Neratinib Puma Biotechnology | 69 | 1 |
| 4.5.1.1 Drug Forecast | 69 | 1 |
| 4.5.2 AZD-4736 AstraZeneca | 70 | 1 |
| 4.5.2.1 Drug Forecast | 70 | 1 |
| 4.5.3 LY2835219 Eli Lilly | 71 | 1 |
| 4.5.3.1 Drug Forecast | 71 | 1 |
| 4.5.4 LEE-011 Novartis | 72 | 1 |
| 4.5.4.1 Drug Forecast | 72 | 1 |
| 4.5.5 JNJ-56021927 Johnson &Johnson | 73 | 1 |
| 4.5.5.1 Drug Forecast | 73 | 1 |
| 4.5.6 Tremelimumab AstraZeneca | 74 | 1 |
| 4.5.6.1 Drug Forecast | 74 | 1 |
| 4.5.7 Margetuximab Macrogenics | 75 | 1 |
| 4.5.7.1 Drug Forecast | 75 | 1 |
| 4.5.8 Conclusion | 76 | 1 |
| 5 Multi-scenario Market Forecast to 2021 | 77 | 21 |
| 5.1 Overall Market Size | 77 | 2 |
| 5.2 Generic Penetration | 79 | 3 |
| 5.3 Revenue Forecast by Molecular Target | 82 | 1 |
| 5.3.1 Epidermal Growth Factor Receptors | 82 | 1 |
| 5.3.2 Cyclin-Dependent Kinase 4 and 6 | 83 | 1 |
| 5.3.3 Programmed Cell Death Protein 1 Inhibitor | 83 | 1 |
| 5.3.4 VEGF Inhibitors | 84 | 1 |
| 5.3.5 ALK Tyrosine Kinase Receptor | 85 | 1 |
| 5.3.6 Androgen Receptor Antagonists | 86 | 1 |
| 5.4 Revenue and Market Share Analysis by Company | 87 | 4 |
| 5.4.1 Roche To What Extent Will Newly Approved and Pipeline Product Approvals Offset Avastin s and Herceptin s Patent Expiries? | 91 | 1 |
| 5.4.2 Novartis Markets Blockbuster Drugs, but How Much of These Revenues Are Related to Non-hematological Cancers? | 92 | 2 |
| 5.4.3 Bristol-Myers What Does Limited Product Selection for Non-hematological Cancers Mean for Revenues? | 94 | 1 |
| 5.4.4 Pfizer What Do Patent Expiries Mean for Pfizer? | 95 | 1 |
| 5.4.5 Astellas Tarceva s Expiry Effects | 96 | 1 |
| 5.4.6 Amgen Growth Despite Multiple Patent Expiries | 97 | 1 |
| 6 Company Analysis and Positioning | 98 | 3 |
| 6.1 Company Landscape | 98 | 1 |
| 6.2 Marketed and Pipeline Portfolio Analysis | 99 | 2 |
| 7 Strategic Consolidations | 101 | 20 |
| 7.1 Licensing Deals | 101 | 1 |
| 7.1.1 Deals by Region, Year and Value | 101 | 2 |
| 7.1.2 Deals by Stage of Development and Value | 103 | 1 |
| 7.1.3 Deals by Molecule Type, Mechanism of Action and Value | 104 | 2 |
| 7.1.4 Table for Licensing Deals Valued Above $100m | 106 | 6 |
| 7.2 Co-development Deals | 112 | 1 |
| 7.2.1 Deals by Region, Year and Value | 112 | 2 |
| 7.2.2 Deals by Stage of Development and Value | 114 | 1 |
| 7.2.3 Deals by Molecule Type, Mechanism of Action and Value | 115 | 2 |
| 7.2.4 Table for Co-development Deals Valued Above $100m | 117 | 4 |
| 8 Appendix | 121 | 63 |
| 8.1 References | 121 | 13 |
| 8.2 Table of All Clinical Stage Pipeline Products | 134 | 46 |
| 8.3 Abbreviations | 180 | 1 |
| 8.4 Methodology | 181 | 3 |
| 8.4.1 Coverage | 181 | 1 |
| 8.4.2 Secondary Research | 182 | 1 |
| 8.4.3 Market Size and Revenue Forecasts | 182 | 1 |
| 8.4.4 Pipeline Analysis | 182 | 1 |
| 8.4.5 Competitive Landscape | 183 | 1 |
| 8.5 Contact Us | 183 | 1 |
| 8.6 Disclaimer | 183 | 1 |
